Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Hepatitis B | Research

Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018

Authors: Soledad Colombe, Maria Axelsson, Soo Aleman, Ann-Sofi Duberg, Josefine Lundberg Ederth, Viktor Dahl

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Introduction

To monitor Sweden’s progress towards the WHO goal of eliminating viral hepatitis, we estimated the prevalence, notification rate, and liver-related morbidity and mortality for diagnosed hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in 2015 and 2018.

Methods

We identified cases of hepatitis B and C within the National System for Notifiable Diseases and obtained data on treatment and whether the case was deceased or not. We calculated prevalence, notification rates per 100,000, and proportion of newly diagnosed cases of hepatitis with liver disease at the time of diagnosis, and proportion of all deceased cases who died from liver disease. We calculated Poisson 95% confidence intervals (CIs) around the notification rates and Wilson 95% CIs around prevalence and mortality estimates.

Results

In 2015 and 2018, the prevalence of diagnosed HBV infections was 0.20% [95% CI: 0.19–0.20] and 0.21% [0.20–0.21]. Notification rates per 100,000 for HBV infections were 13.02 [12.32–13.76] and 7.71 [7.18–8.27]. HBV liver-related morbidity was 2.65% [1.90–3.68] and 2.16% [1.35–3.43]. HBV liver-related mortality was 20.00% [14.81–26.44] and 17.95% [13.20–23.94]. In 2015 and 2018, the prevalence of diagnosed HCV-infections was 0.24% [0.24–0.25] and 0.18% [0.18–0.19]. Notification rates per 100,000 for HCV infections were 15.92 [15.14–16.73] and 13.05 [12.36–13.77]. HCV liver–related morbidity was 8.14% [6.89–9.60] and 3.90% [2.99–5.08]. HCV liver–related mortality was 27.08% [24.54–29.77] and 26.90% [24.12–29.88].

Conclusions

All indicators decreased or remained stable between 2015 and 2018, indicating progress in the elimination of viral hepatitis, especially for HCV infection.
Literature
1.
go back to reference WHO—Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. 2016 WHO—Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. 2016
2.
go back to reference WHO - Monitoring and Evaluation for Viral Hepatitis B and C: recommended indicators and framework. Technical report. 2016. WHO - Monitoring and Evaluation for Viral Hepatitis B and C: recommended indicators and framework. Technical report. 2016.
6.
go back to reference Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefPubMed Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefPubMed
7.
go back to reference Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.CrossRef Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.CrossRef
9.
go back to reference Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50(2):233–44.CrossRefPubMed Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50(2):233–44.CrossRefPubMed
11.
go back to reference Westin J, Aleman S, Castedal M, Duberg AS, Eilard A, Fischler B, et al. Management of hepatitis B virus infection, updated Swedish guidelines. Infect Dis. 2020;52(1):1–22.CrossRef Westin J, Aleman S, Castedal M, Duberg AS, Eilard A, Fischler B, et al. Management of hepatitis B virus infection, updated Swedish guidelines. Infect Dis. 2020;52(1):1–22.CrossRef
12.
go back to reference Kåberg M, Navér G, Hammarberg A, Weiland O. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. J Viral Hepat. 2018;25(12):1452–61.CrossRefPubMed Kåberg M, Navér G, Hammarberg A, Weiland O. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. J Viral Hepat. 2018;25(12):1452–61.CrossRefPubMed
13.
go back to reference Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J, for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 017. Infect Dis. 2018;50(8):569–83.CrossRef Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J, for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 017. Infect Dis. 2018;50(8):569–83.CrossRef
20.
go back to reference Aisyah DN, Shallcross L, Hully AJ, O’Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat. 2018;25(6):680–98.CrossRefPubMed Aisyah DN, Shallcross L, Hully AJ, O’Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat. 2018;25(6):680–98.CrossRefPubMed
21.
go back to reference Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepat. 2022;76(6):1249–62.CrossRef Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepat. 2022;76(6):1249–62.CrossRef
24.
go back to reference Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33.CrossRefPubMed Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33.CrossRefPubMed
28.
go back to reference Duberg AS, Törner A, Davidsdóttir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008;15(7):538–50.CrossRefPubMed Duberg AS, Törner A, Davidsdóttir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008;15(7):538–50.CrossRefPubMed
29.
go back to reference Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643–57.CrossRefPubMed Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643–57.CrossRefPubMed
Metadata
Title
Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018
Authors
Soledad Colombe
Maria Axelsson
Soo Aleman
Ann-Sofi Duberg
Josefine Lundberg Ederth
Viktor Dahl
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07886-2

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.